| Literature DB >> 28203117 |
Nur Fatiha Norhisham1, Choi Yen Chong1, Sabreena Safuan1.
Abstract
BACKGROUND: Detection of vascular invasion by hematoxylin and eosin staining is the current pathological assessment practice to diagnose breast carcinoma. However, conventional hematoxylin and eosin staining failed to distinguish between blood vessel invasion and lymphatic vessel invasion. Both are important prognostic criteria however with different outcomes. The aim of this study is to distinguish between blood vessel invasion and lymphatic vessel invasion using conventional assessment and immunohistochemical markers. The prognostic significance of both circulatory invasions in invasive breast carcinoma was also investigated.Entities:
Keywords: Breast carcinoma; CD34; D2-40; Lymphatic invasion
Year: 2017 PMID: 28203117 PMCID: PMC5301373 DOI: 10.1186/s12907-017-0041-4
Source DB: PubMed Journal: BMC Clin Pathol ISSN: 1472-6890
Clinicopathological characteristics of breast carcinoma patients and tumors
| Clinical criteria | Frequency, n (%) | Clinical criteria | Frequency, n (%) |
|---|---|---|---|
| Age of diagnosis | Recurrence | ||
| ≤40 | 4 (6.9) | No | 56 (96.6) |
| ≥40 | 54 (93.1) | Yes | 2 (3.4) |
| Ethnicity | Estrogen Receptor | ||
| Malay | 54 (93.1) | Positive | 32 (55.2) |
| Chinese | 4 (6.9) | Negative | 26 (44.8) |
| Tumor Size (mm) | Progesteron Receptor | ||
| <30 | 11 (19.0) | Positive | 28 (48.3) |
| 30 ≤ × < 60 | 27 (46.6) | Negative | 30 (51.7) |
| >60 | 17 (29.3) | ||
| No data | 3 (5.1) | ||
| Tumor Grading | Lymph nodes involvement | ||
| Grade I | 10 (17.2) | 1 | 19 (32.8) |
| Grade II | 27 (46.6) | 2-4 | 6 (10.3) |
| Grade III | 16 (27.6) | >4 | 16 (27.6) |
| Not determined | 5 (8.6) | Not involved | 17 (29.3) |
| Distant Metastasis | Lymphovascular Invasion (H&E) | ||
| Yes | 15 (25.9) | Positive | 26 (44.8) |
| No | 37 (63.8) | Negative | 28 (48.3) |
| Not determined | 6 (10.3) | Not determined | 4 (6.9) |
| Mastectomy | |||
| Full | 10 (17.2) | ||
| Partial | 48 (82.8) | ||
Fig. 1Example of true positive lymphatic vessel invasion determined in D2-40 stained tissue. H&E stained tissue scored as positive lymphovascular invasion (a). At the same field of microscopic field view (200× magnification), lymphatic vessel invasion was clearly observed in D2-40 stained tissue (b). In CD34 stained tissue (c), blood vessel invasion was scored as negative
Fig. 2H&E (a), D2-40 (b) and CD-34 (c) staining of consecutive tissue section. This sample was scored as lymphovascular invasion negative by H&E. However, CD34 staining (c) clearly showed the presence of tumor cells within CD34 stained vessel and was scored as blood vessel invasion positive. Lymphatic invasion was scored as negative (b). Noted that IHC was able to distinguih between lymphatic and blood vessel invasion. (200× magnification)
Association of lymphatic vessel density with clinical criteria
| Total LVD | Intra-tumoral LVD | Peri-tumoural LVD | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Low | High |
| Low | High |
| Low | High |
| ||
| Age | <40 | 0 (0.0) | 4 (13.3) |
| 2 (7.4) | 2 (6.9) | 0.941 | 0 (0.0) | 4 (13.8) |
|
| ≥40 | 27 (100.0) | 26 (86.7) | 25 (92.6) | 27 (93.1) | 28 (100.0) | 2 (86.2) | ||||
| Tumor size | <30 | 2 (7.7) | 9 (31.0) | 0.080 | 3 (11.1) | 8 (28.6) | 0.255 | 3 (11.1) | 8 (28.6) | 0.255 |
| 30 ≤ × < 60 | 15 (57.7) | 12 (41.4) | 15 (55.6) | 12 (42.9) | 15 (55.6) | 12 (42.9) | ||||
| 60 ≥ | 9 (34.6) | 8 (27.6) | 9 (33.3) | 8 (28.6) | 9 (33.3) | 8 (28.6) | ||||
| Grade | I | 2 (7.7) | 8 (26.7) |
| 1 (3.7) | 9 (31.0) |
| 13 (11.1) | 7 (24.1) | 0.079 |
| II | 13 (50.0) | 14 (46.7) | 15 (55.6) | 12 (41.4) | 14 (51.9) | 13 (44.8) | ||||
| III | 11 (42.3) | 5 (16.7) | 10 (37.0) | 6 (20.7) | 10 (37.0) | 6 (20.7) | ||||
| No grade | 0 | 3 (10.0) | 1 (3.7) | 2 (6.9) | 0 | 3 (10.3) | ||||
| Distant metastasis | Yes | 7 (25.9) | 8 (27.6) | 0.989 | 8 (29.6) | 7 (23.3) | 0.065 | 7 (25.0) | 8 (27.6) |
|
| No | 18 (66.7) | 19 (65.5) | 19 (70.4) | 19 (63.3) | 21 (75.0) | 17 (58.6) | ||||
| Not determine | 2 (7.4) | 2 (6.9) | 0 | 4 (13.3) | 0 | 4 (13.8) | ||||
| Recurrence | No | 26 (96.3) | 29 (96.7) | 0.940 | 27 (100) | 27 (93.1) | 0.1 | 27 (96.4) | 28 (96.6) | 0.980 |
| Yes | 1 (3.7) | 1 (3.3) | 0 | 2 (6.9) | 1 (3.6) | 1 (3.4) | ||||
| ER | Positive | 16 (61.5) | 16 (55.2) | 0.632 | 16 (61.5) | 15 (53.6) | 0.554 | 17 (63.0) | 15 (53.6) | 0.480 |
| Negative | 10 (38.5) | 13 (44.8) | 10 (38.5) | 13 (46.4) | 10 (37.0) | 13 (46.4) | ||||
| PR | Positive | 15 (55.6) | 13 (44.8) | 0.422 | 13 (48.1) | 14 (50.0) | 0.891 | 16 (57.1) | 12 (42.9) | 0.284 |
| Negative | 12 (44.4) | 16 (55.2) | 14 (51.9) | 14 (50.0) | 12 (42.9) | 16 (57.1) | ||||
| Lymph nodes involvement | 0 | 8 (29.6) | 11 (37.9) | 0.374 | 8 (30.8) | 11 (37.9) | 0.678 | 7 (25.0) | 12 (42.9) | 0.266 |
| 1 | 3 (11.1) | 3 (10.3) | 3 (11.5) | 3 (10.3) | 4 (14.3) | 2 (7.1) | ||||
| 2 to 4 | 6 (22.2) | 10 (34.5) | 6 (23.1) | 10 (31.0) | 7 (25) | 9 (32.1) | ||||
| >4 | 10 (37.0) | 5 (17.2) | 9 (34.6) | 6 (20.7) | 10 (35.7) | 5 (17.9) | ||||
*Bold datas refer to statistically significant association (p<0.05)
Association of lymphatic vessel invasion with clinical criteria
| Intra-tumoral LVI | Peri-tumoral LVI | Total LVI | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Positive | Negative |
| Positive | Negative |
| Positive | Negative |
| ||
| Age | <40 | 2 (7.1) | 2 (7.1) | 1.0 | 4 (14.8) | 0 (0) |
| 4 (10.5) | 0 (0) | 0.065 |
| ≥40 | 26 (92.9) | 26 (92.9) | 23 (85.2) | 30 (100) | 34 (89.5) | 19 (100) | ||||
| Tumor size | <30 | 7 (25) | 4 (14.8) | 0.548 | 4 (14.8) | 7 (25) | 0.636 | 9 (23.7) | 2 (11.8) | 0.497 |
| 30 ≤ × < 60 | 12 (42.9) | 15 (55.6) | 14 (51.9) | 13 (46.4) | 17 (44.7) | 10 (58.8) | ||||
| 60 ≥ | 9 (32.1) | 8 (29.6) | 9 (33.3) | 8 (28.6) | 12 (31.6) | 5 (29.4) | ||||
| Grade | I | 3 (10.7) | 7 (25.0) | 0.387 | 5 (18.5) | 5 (17.2) | 0.197 | 5 (13.2) | 5 (27.8) | 0.607 |
| II | 14 (50.0) | 13 (46.4) | 15 (55.6) | 12 (41.4) | 19 (50) | 8 (44.4) | ||||
| III | 10 (35.7) | 6 (21.4) | 7 (25.9) | 9 (31.0) | 12 (31.6) | 4 (22.2) | ||||
| No grade | 1 (3.33) | 2 (7.1) | 0 | 3 (10.3) | 2 (5.3) | 1 (5.6) | ||||
| Distant metastasis | Yes | 9 (32.1) | 6 (21.4) | 0.432 | 7 (25.9) | 8 (26.7) |
| 11 (28.9) | 4 (21.1 | 0.607 |
| No | 18 (64.3) | 19 (67.9) | 20 (74.1) | 18 (60.0) | 25 (65.8) | 13 (68.4) | ||||
| Not determine | 1 (3.6) | 3 (10.7) | 0 | 4 (13.3) | 2 (5.3) | 2 (10.5) | ||||
| Recurrence | No | 26 (92.9) | 28 (100) | 0.92 | 27 (100) | 28 (93.3) | 0.105 | 36 (94.7) | 19 (100) | 0.198 |
| Yes | 2 (7.1) | 0 | 0 | 2 (6.7) | 2 (5.3) | 0 | ||||
| ER | Positive | 16 (59.3) | 15 (55.6) | 0.632 | 15 (57.7) | 17 (58.6) | 0.944 | 21 (56.8) | 11 (61.1) | 0.738 |
| Negative | 11 (40.7) | 12 (44.4) | 11 (42.3) | 2 (41.4) | 16 (43.2) | 7 (38.9) | ||||
| PR | Positive | 13 (46.4) | 14 (51.9) | 0.687 | 13 (48.1) | 15 (51.7) | 0.789 | 17 (44.7) | 11 (61.1) | 0.251 |
| Negative | 15 (53.6) | 13 (48.1) | 14 (51.9) | 14 (48.3) | 21 (55.3) | 7 (38.9) | ||||
| Lymph nodes involvement | 0 | 10 (37.0) | 9 (32.1) | 0.983 | 7 (25.9) | 12 (41.4) | 0.088 | 13 (35.1) | 6 (31.6) | 0.763 |
| 1 | 3 (11.1) | 3 (10.7) | 1 (3.7) | 5 (17.2) | 3 (8.1) | 3 (15.8) | ||||
| 2 to 4 | 7 (25.9) | 8 (28.6) | 11 (40.7) | 5 (17.2) | 10 (27) | 6 (31.6) | ||||
| >4 | 7 (25.9) | 8 (28.6) | 8 (29.6) | 7 (24.1) | 11 (29.7) | 4 (21.1) | ||||
*Bold datas refer to statistically significant association (p<0.05)